PI3 K inhibitor
Relay Therapeutics Advances PI3K Inhibitor for Breast Cancer Subgroup with Promising Early Trial Results
Relay Therapeutics, PI3K inhibitor, breast cancer, RLY-2608, metastatic breast cancer, PI3Ka mutations, clinical trial
FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment
Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative